Monitor the Investor Day on June 1 for quantitative guidance on the HIFU growth trajectory and the financial impact of discontinuing ESWL/Distribution segments. Watch Q2 2026 filing for restated historicals and segment-level financial breakdowns. The ticker change to FOCL may prompt re-indexing and retail attention.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · May 29 $4.32entry
- T+1 · 6mo ago +10.65%α +10.39% · $4.78
- T+5 · 6mo ago +6.25%α +8.77% · $4.59
- T+20 · 5mo ago +18.06%α +19.85% · $5.10
- T+60 · due 3mo ago Pending
Price Chart
How similar events traded
Executive Summary
EDAP TMS SA announced it will operate under the new corporate name 'FocalTherics' and change its Nasdaq ticker to 'FOCL' effective June 1, 2026. The company also intends to classify its legacy ESWL and Distribution segments as discontinued operations beginning Q2 2026, concentrating on its robotic HIFU focal therapy business. An Investor Day is scheduled for June 1 to discuss strategy. The filing contains no financial data, and the historical record shows prior neutral reports on this ticker have been directionally unhelpful, though the name/segmentation pivot is a notable strategic move.
Key Facts
- Ticker symbol changes from EDAP to FOCL effective June 1, 2026.
- Company will operate under new corporate name 'FocalTherics'.
- Legal name remains EDAP TMS S.A.; shareholder vote required for legal name change.
- ESWL and Distribution segments to be classified as discontinued operations beginning Q2 2026.
- Investor Day scheduled for June 1, 2026 at 8:00 AM ET.
- No financial figures or guidance provided in the filing.
- CUSIP number unchanged; no shareholder action required for name/ticker change.
Financial Impact
No financial figures disclosed; the strategic pivot to focus on robotic HIFU could materially reshape the revenue and cost structure once the discontinued operations classification is implemented in Q2 2026 financials.
Risk Factors
- Execution risk in transitioning to a pure-play focal therapy company from legacy segments.
- Potential for customer or distributor disputes during the discontinuation process.
- No financial details provided, the strategic benefit may take quarters to materialize.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-003773 |
| Exhibit: exh_991.htm | 0001171843-26-003773 |
| Document: 0001171843-26-003773-index-headers.html | 0001171843-26-003773 |
| Document: 0001171843-26-003773-index.html | 0001171843-26-003773 |
| Document: 0001171843-26-003773.txt | 0001171843-26-003773 |
Track record
12 reports on EDAP
The track record builds as more bullish or bearish reports settle.
Filters
- Aug 17, 202613w ago Insider Cluster Mixed 5/10 No price data
- May 29, 202624w ago 8-K Neutral 4/10 Viewing Entry $4.32 to $5.10 ▲ +18.06% +19.85% vs SPY
- May 14, 202626w ago DEFA14A Bearish 6/10 Entry $4.13 to $4.77 ▼ −15.50% −16.35% vs SPY
- May 14, 202626w ago DEFA14A Neutral 3/10 Entry $4.13 to $4.77 ▲ +15.50% +16.35% vs SPY
- May 14, 202626w ago Press Release Neutral 3/10 Entry $4.13 to $4.77 ▲ +15.50% +16.35% vs SPY
- May 7, 202627w ago 8-K Mixed 6/10 Entry $4.16 to $4.69 ▲ +12.74% +9.60% vs SPY
- Apr 16, 202630w ago Press Release Neutral 1/10 Entry $3.59 to $4.16 ▲ +15.88% +10.06% vs SPY
- Apr 1, 202632w ago EFFECT Neutral 4/10 Entry $3.53 to $3.31 ▼ −6.23% −15.95% vs SPY
- Mar 26, 202633w ago S-3/A Neutral 4/10 Entry $3.73 to $3.22 ▼ −13.67% −26.41% vs SPY
- Mar 25, 202633w ago S-3 Neutral 5/10 Entry $3.77 to $3.22 ▼ −14.59% −25.25% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers